subscribeSubscribe
X4 enters commercial fold with FDA approval of rare disease drug Xolremdi

X4 enters commercial fold with FDA approval of rare disease drug Xolremdi

FIERCE PHARMA
30 Apr 2024
Share Share
PANTHERx® Rare Partnering with X4 for XOLREMDI™ Distribution

PANTHERx® Rare Partnering with X4 for XOLREMDI™ Distribution
PR NEWSWIRE
29 Apr 2024
Share Share
X4 Pharma`s XOLREMDI™ Approved by FDA for WHIM Syndrome

X4 Pharma`s XOLREMDI™ Approved by FDA for WHIM Syndrome
GLOBENEWSWIRE
29 Apr 2024
Share Share
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results
GLOBENEWSWIRE
21 Mar 2024
Share Share
X4 Pharma Announces Presentation of Data from Mavorixafor Phase 2 Trial

X4 Pharma Announces Presentation of Data from Mavorixafor Phase 2 Trial
GLOBENEWSWIRE
09 Dec 2023
Share Share
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review for Mavorixafor

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review for Mavorixafor
GLOBENEWSWIRE
31 Oct 2023
Share Share
X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight for Mavorixafor

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight for Mavorixafor
GLOBENEWSWIRE
12 Dec 2022
Share Share
X4 scores a phase 3 win for immune deficiency disorder drug

X4 scores a phase 3 win for immune deficiency disorder drug
Annalee Armstrong FIERCEBIOTECH
30 Nov 2022
Share Share
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global

X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global
GLOBENEWSWIRE
29 Nov 2022
Share Share
X4 Pharmaceuticals Host Investor Webinar Highlighting New Mavorixafor Phase 1b

X4 Pharmaceuticals Host Investor Webinar Highlighting New Mavorixafor Phase 1b
GLOBENEWSWIRE
31 Aug 2022
Share Share